Drug Profile
Research programme: melanocortin type 4 receptor agonists - GlaxoSmithKline
Alternative Names: GSK 0052; GSK 171BLatest Information Update: 06 Jan 2009
Price :
$50
*
At a glance
- Originator Novartis
- Developer GlaxoSmithKline; Novartis
- Class Azepines; Guanidines; Small molecules
- Mechanism of Action Melanocortin type 4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 20 Apr 2006 Chiron Corporation has been acquired and merged into Novartis
- 08 Jan 2003 Preclinical trials in Obesity in USA (unspecified route)